Adverse Events of Afatinib as First-line Treatment for Five Cases of Advanced
Lung Adenocarcinoma and Review of Literature

Adverse Events of Afatinib as First-line Treatment for Five Cases of Advanced
Lung Adenocarcinoma and Review of Literature

Background and objective Afatinib is an irreversible ErbB-family blocker with a clinical activity in non-small cell lung cancer with epidermal growth factor receptor (EGFR) mutations. The aim of this study is to assess the safety of afatinib in patients with advanced lung adenocarcinoma. Methods Pat...

Full description

Bibliographic Details
Main Authors: Hong TAO, Lili GUO, Junfang TANG, Yunzhong ZHU, Liyan XU, Qiyi MENG, Wei WU, Mingzhi LI, Weihua WU, Li TONG, Hongbo WU, Liang SHI, Zhe LIU
Format: Article
Language:zho
Published: Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2014-04-01
Series:Chinese Journal of Lung Cancer
Subjects:
Afatinib
Epidermal growth factor receptor
Tyrosine kinase inhibitor
Lung neoplasms
Adverse event
Online Access:http://dx.doi.org/10.3779/j.issn.1009-3419.2014.04.09

Similar Items

Similar Items